Processa Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Common Share, Disclosure: Schedule of Earnings Per Share (Tables)

3 Months Ended

Mar. 31, 2017

	Three months ended March 31,
	2017		2016
Net loss from continuing operations	$	(75,627)	$	(131,621)
Net loss from discontinued operations		--		(2,004)
Net Loss		(75,627)		(133,625)
Basic and diluted:
Preferred stock cumulative dividend - Series D		(10,588)		(10,705)
Income applicable to preferred stockholders		(10,588)		(10,705)
Net loss applicable to common stockholders	$	(86,215)	$	(144,330)